A Study of Auxora in Patients With Critical COVID-19 Pneumonia

• ClinicalTrials.gov Identifier: NCT04661540
• Recruitment Status: Completed
• First Posted: December 10, 2020
• Last Update Posted: August 18, 2022
• Sponsor: CalciMedica, Inc.
• Collaborator: Northwestern University
• Information provided by (Responsible Party): CalciMedica, Inc.

Study Description

Brief Summary:

This is a single-blind study consisting of up to 3 cohorts Patients will be randomized 3:1 to Auxora or Placebo. The first 4 patients will be enrolled in Cohort 1. If dose escalation occurs, the next 4 patients will be enrolled in Cohort 2 If dose escalation occurs, the next 8 patients will be enrolled in Cohort 3. The decision to escalate dosing will be made by CalciMedica in consultation with the PI and after the review of safety events in Cohorts 1 and 2.

Condition or disease	Intervention/treatment	Phase
Pneumonia	Drug: CM4620-IE (Injectable Emulsion); Drug: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 9 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: A Single-Blind Dose-Ranging Pharmacodynamic Study of Auxora for the Treatment of Patients With Critical COVID-19 Pneumonia
• Actual Study Start Date: March 2, 2021
• Actual Primary Completion Date: May 9, 2021
• Actual Study Completion Date: November 2, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Auxora; Auxora will be given as a continuous infusion: Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours; After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours	Drug: CM4620-IE (Injectable Emulsion); Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion; Other Name: Auxora
Placebo Comparator: Placebo; Placebo will be given as a continuous infusion: Day 1: All 3 cohorts will receive 1.25 mL/kg over 4 hours. After initial infusion is complete, Cohort 3 will receive a continuous infusion of 1.0 mL/kg/24 hours for 96 hours Day 2: Cohort 1 will receive 1.0 mL/kg over 4 hours; Cohort 2 will receive 1.25mL/kg over 4 hours Day 3: Cohort 1 and 2 will receive 1.0 mL/kg over 4 hours Day 4: Cohort 2 will receive 1.0 mL/kg over 4 hours	Drug: Placebo; Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion

Outcome Measures

Primary Outcome Measures :

1. Proportion of immune cells in BAL fluid and T cell activation will be assessed [ Time Frame: Baseline Assessment up to 120 hours ]
2. Impact of Auxora on the emergence of new clusters/cell types/cell states [ Time Frame: Baseline Assessment up to 120 hours ]
3. Impact of Auxora on detection of SARS-CoV-2 positive and negative strand RNA in infected cells [ Time Frame: Baseline Assessment up to 60 days ]

Secondary Outcome Measures :

1. Plasma Levels of CM4620 [ Time Frame: From end of first infusion of study drug up to 144 hours ]
   Concentration of Auxora from blood samples and fluid collected from BAL
2. Number of Days on Mechanical Ventilation after randomization [ Time Frame: From randomization until patient is extubated assessed up to 60 days ]
3. Number of Days in the Hospital after randomization [ Time Frame: From randomization until discharge from the hospital assessed up to 60 days ]
4. Number of Days in the Intensive Care Unit (ICU) after randomization [ Time Frame: From randomization until discharge from ICU assessed up to 60 days ]
5. Pre-defined changes in cardiac conduction assessed by ECG [ Time Frame: From screening up to 144 hours ]
   Changes in cardiac conduction are defined as: QTcF interval of ≥ 500 msec; QTcF prolongation of ≥ 60 msec as compared to baseline; Mobitz Type II second degree atrioventricular (AV) block; Third degree or high grade AV block; or Polymorphic Ventricular Tachycardia
6. Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: From randomization up to 60 days ]
7. Intensity and relationship of TEAEs and SAEs [ Time Frame: From randomization up to 60 days ]
8. Mortality [ Time Frame: Randomization up to 60 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen;

2. Moderate ARDS characterized by the following criteria:

   • Invasive mechanical ventilation with a minimum PEEP of 5 cm H2O;
   • PaO2/FiO2 ≤200 that may be estimated from pulse oximetry or determined by arterial blood gas;
   • No evidence of volume overload or heart failure;
3. The patient is ≥18 years of age at the time of consent;
4. QTcF interval ≤ 440 milliseconds;
5. A female patient of childbearing potential must not attempt to become pregnant for 39 months, and if sexually active with a male partner, is willing to practice acceptable methods of birth control for 39 months after the last dose of study drug;
6. A male patient who is sexually active with a female partner of childbearing potential is willing to practice acceptable methods of birth control for 39 months after the last dose of study drug. A male patient must not donate sperm for 39 months;
7. The patient is willing and able to, or has a legal authorized representative (LAR) who is willing and able to, provide informed consent to participate, and to cooperate with all aspects of the protocol.

Exclusion Criteria:

1. Expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days.
2. ECMO;
3. Suspected septic shock;

4. The patient has a history of:

   • Organ or hematologic transplant;
   • HIV;
   • Active hepatitis B or hepatitis C infection;

5. Current treatment with:

   • Chemotherapy;
   • Immunosuppressive medications or immunotherapy (see Section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent;
   • Hemodialysis or Peritoneal Dialysis;
6. The patient is known to be pregnant or is nursing;
7. Currently participating in another study of an investigational drug or therapeutic medical device at the time of consent;
8. Allergy to eggs or any of the excipients in study drug.

Contacts and Locations

Locations

United States, Illinois

Northwestern Memorial Hospital

Chicago, Illinois, United States, 60611

Sponsors and Collaborators

CalciMedica, Inc.

Northwestern University

More Information

• Responsible Party: CalciMedica, Inc.
• ClinicalTrials.gov Identifier: NCT04661540
• Other Study ID Numbers: CM4620-205
• First Posted: December 10, 2020
• Last Update Posted: August 18, 2022
• Last Verified: May 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by CalciMedica, Inc.:

COVID-19; Coronavirus; Pneumonia; Calcium Release-Activated Calcium Channel (CRAC) Inhibitors; CM4620; Auxora

Additional relevant MeSH terms:

COVID-19; Pneumonia; Pneumonia, Viral; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases